CAR-Exosome Development Services for Cell-Free CAR-Immunotherapy

Online Inquiry

Background Service Service Packages Workflow Highlights FAQs Contact

Despite the transformative promise of CAR-T therapy, clinical translation remains hindered by severe cytokine release syndrome, poor infiltration into solid tumor stroma, and the logistical complexity of autologous manufacturing. Our CAR-Exosome Development platform addresses these critical bottlenecks by engineering cell-free nanovesicles that retain potent tumor-targeting capacity while eliminating cellular toxicity risks. We provide a comprehensive suite of services, from precision CAR-protein enrichment and synergistic payload co-loading to head-to-head comparative potency profiling against parental CAR-T cells. This integrated approach accelerates your next-generation immunotherapy journey by delivering off-the-shelf scalability, enhanced solid tumor penetration, and reduced safety liability.

Introduction

The CAR-Exosome approach involves leveraging nano-scale vesicles secreted by engineered CAR-expressing cells, which carry the functional CAR complex along with cytotoxic payloads to enable targeted anti-tumor activity. Cell-Free CAR-Immunotherapy, therefore, represents a paradigm shift from traditional living cell therapies by utilizing these acellular vesicles as a safer, "off-the-shelf" platform capable of effective tumor killing while mitigating the risks associated with replicating cells.

Fig.1 Advancing cell-free CAR immunotherapy through exosome-mediated delivery. (Creative Biolabs Original) Fig.1 Development of exosome-based platforms for cell-free CAR immunotherapy.

CAR-Exosome Development for Cell-Free CAR-Immunotherapy at Creative Biolabs

Creative Biolabs provides a comprehensive suite of deliverables designed to transition your project from traditional cell therapy to a streamlined, cell-free modality. By utilizing exosomes derived from CAR-engineered T, NK, or Macrophage cells, we provide biological "nanoscale vanguards" that inherit the targeting specificity of parent cells without the risks of uncontrolled cell expansion.

Service Packages

Precision CAR-Protein Enrichment & Exosomal Sorting Technology

Our proprietary platform enables targeted enrichment of CAR proteins onto exosomal membranes, ensuring optimal display density and functional orientation. This technology addresses the critical challenge of maximizing CAR density on nanosized vesicles, delivering enhanced tumor recognition and binding avidity while maintaining the natural homing capabilities of exosomes. Applications include developing off-the-shelf CAR therapeutics with improved tumor penetration and reduced immunogenicity.

Learn More →

Co-loading of Pro-apoptotic Payloads for CAR-Exosome Synergistic Lysis

We offer integrated payload loading strategies that combine CAR-mediated targeting with complementary pro-apoptotic molecules, including chemotherapeutics, siRNA, or death receptor agonists, within single exosomal carriers. This multimodal approach enables synergistic tumor killing through parallel cytotoxic pathways, overcoming resistance mechanisms commonly encountered with single-agent therapies. Ideal for solid tumor applications requiring multifaceted therapeutic attack.

Learn More →

Comparative Potency Profiling: CAR-Exosomes vs. Parental CAR-T Cells

Our standardized head-to-head profiling platform delivers quantitative comparisons between CAR-exosomes and their parental CAR-T cells across critical functional parameters, including acute cytotoxicity, serial killing capacity, exhaustion kinetics, and tumor microenvironment resistance. This service provides essential datasets for determining optimal therapeutic format selection, regulatory filing strategies, and mechanistic understanding of acellular immunotherapy performance.

Learn More →

Our Service Process

Required Starting Materials:

Specific CAR-gene sequences or established CAR-cell lines.
Targeted tumor cell lines or antigen profile data for validation.

Key Steps:

Workflow of CAR-exosome development for cell-free CAR-immunotherapy at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables: You will receive a high-purity CAR-exosome preparation, a detailed analytical report, and a comprehensive functional validation dossier.

Key Advantages

Superior Safety Profile: As cell-free entities, CAR-Exosomes lack the ability to proliferate, thereby eliminating the risk of CRS and on-target off-tumor toxicity typically associated with live cell therapies.
True "Off-the-Shelf" Availability: Their nano-sized structure allows for scalable manufacturing, long-term storage, and cryopreservation without loss of function, enabling immediate allogeneic use without requiring personalized production.
Enhanced Solid Tumor Penetration: The small diameter of exosomes facilitates efficient extravasation and deep penetration into the dense extracellular matrix of solid tumors, overcoming a major physical barrier faced by whole cells.

FAQs

Q1: Can CAR-exosomes function as multifunctional delivery vehicles beyond direct tumor targeting?

A1: Absolutely. Our platform integrates dual functionality—surface display of CARs for precise tumor recognition alongside internal encapsulation of diverse therapeutic payloads, including cytotoxic small molecules, gene-silencing siRNAs, or immunomodulatory proteins. This combinatorial approach enables synergistic antitumor activity while leveraging the natural biocompatibility of exosomal carriers.

Q2: What strategies ensure stable CAR presentation on exosomal membranes during production and storage?

A2: We employ proprietary EXO-anchor engineering, incorporating specialized membrane-targeting motifs that guide optimal CAR incorporation during exosome biogenesis. These anchors preserve native CAR conformation and maintain stable membrane integration throughout isolation and storage, ensuring consistent target recognition without structural degradation.

Why Choose Us

Partnering with Creative Biolabs grants you access to unparalleled expertise spanning both CAR engineering and exosome biology, cultivated over a decade of dedicated innovation. Our distinctive capabilities include metabolic modulation of parental cells to optimize exosomal potency, coupled with multispecific antibody engineering to achieve superior targeting precision.

How to contact us?

Creative Biolabs delivers a fully integrated CAR-Exosome Development platform, converting the inherent complexity of cell-based therapies into safe, scalable, and highly efficacious cell-free nanomedicines. From initial CAR construct design through final lyophilized product characterization, our scientific team provides dedicated support to accelerate your solid tumor therapeutic programs.

To discuss your specific project requirements or request a customized proposal, please contact our scientific team directly.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.